Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MJR001
MIFTS: 65

Major Depressive Disorder

Categories: Genetic diseases, Mental diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Major Depressive Disorder

About this section

MalaCards integrated aliases for Major Depressive Disorder:

Name: Major Depressive Disorder 57 38 12 76 75 37 29 13 6 15 40 73
Seasonal Affective Disorder 57 12 76 25 75 55 43 15 73
Unipolar Depression 57 75 55 73
Major Depressive Disorder, Response to Citalopram Therapy in 57 6
Unipolar Depression, Susceptibility to 57 6
Single Major Depressive Episode 12 73
Major Depressive Disorder 1 57 73
Major Depressive Disorder 2 57 73
Winter Depression 12 73
Mdd 57 75
Sad 25 75
Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment 57
Major Depressive Disorder with a Seasonal Pattern 25
Seasonal Affective Disorder, Susceptibility to 57
Recurrent Major Depressive Episodes 73
Depression in a Seasonal Pattern 25
Affective Disorder, Seasonal 25
Recurrent Major Depression 12
Depressive Disorder, Major 44
Seasonal Mood Disorder 25
Depression; Seasonal 25
Seasonal Depression 25

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 33


Sources

Summaries for Major Depressive Disorder

About this section
MedlinePlus : 43 Seasonal affective disorder (SAD) is a type of depression that comes and goes with the seasons. It usually starts in the late fall and early winter and goes away during the spring and summer. Some people do have episodes of depression that start in the spring or summer, but that is a lot less common. Symptoms of SAD may include Sadness Gloomy outlook Feeling hopeless, worthless, and irritable Loss of interest or pleasure in activities you used to enjoy Low energy Difficulty sleeping or oversleeping Carbohydrate cravings and weight gain Thoughts of death or suicide SAD is more common in women, young people, and those who live far from the equator. You are also more likely to have SAD if you or your family members have depression. The exact causes of SAD are unknown. Researchers have found that people with SAD may have an imbalance of serotonin, a brain chemical that affects your mood. Their bodies also make too much melatonin, a hormone that regulates sleep, and not enough vitamin D. The main treatment for SAD is light therapy. The idea behind light therapy is to replace the sunshine that you miss during the fall and winter months. You sit in front of a light therapy box every morning to get daily exposure to bright, artificial light. But some people with SAD do not respond to light therapy alone. Antidepressant medicines and talk therapy can reduce SAD symptoms, either alone or combined with light therapy. NIH: National Institute of Mental Health

MalaCards based summary : Major Depressive Disorder, also known as seasonal affective disorder, is related to depression and endogenous depression, and has symptoms including mental and behavioral signs and symptoms and depressive symptoms. An important gene associated with Major Depressive Disorder is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Serotonergic synapse and Neuroscience. The drugs Angiotensin II and Fluoxetine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotype is behavior/neurological.

Disease Ontology : 12 An endogenous depression that is characterized by an all-encompassing low mood accompanied by low self-esteem, and by loss of interest or pleasure in normally enjoyable activities.

Genetics Home Reference : 25 Seasonal affective disorder is a mental health condition that is triggered by the changing of the seasons. This condition is a subtype of major depressive disorder and bipolar disorder. Major depressive disorder is characterized by prolonged sadness and a general lack of interest, while bipolar disorder is characterized by similar depressive episodes alternating with periods of abnormally high energy and activity (hypomania or mania). People with seasonal affective disorder have signs and symptoms of either major depressive disorder or bipolar disorder only during certain months of the year. Major depressive disorder is more common than bipolar disorder among people with seasonal affective disorder. This condition usually begins in a person's twenties or thirties.

UniProtKB/Swiss-Prot : 75 Major depressive disorder: A common psychiatric disorder. It is a complex trait characterized by one or more major depressive episodes without a history of manic, mixed, or hypomanic episodes. A major depressive episode is characterized by at least 2 weeks during which there is a new onset or clear worsening of either depressed mood or loss of interest or pleasure in nearly all activities. Four additional symptoms must also be present including changes in appetite, weight, sleep, and psychomotor activity; decreased energy; feelings of worthlessness or guilt; difficulty thinking, concentrating, or making decisions; or recurrent thoughts of death or suicidal ideation, plans, or attempts. The episode must be accompanied by distress or impairment in social, occupational, or other important areas of functioning.

Wikipedia : 76 Major depressive disorder (MDD), also known simply as depression, is a mental disorder characterized by... more...

Description from OMIM: 608516
Sources

Related Diseases for Major Depressive Disorder

About this section

Diseases in the Major Depressive Disorder family:

Major Depressive Disorder 1 Major Depressive Disorder 2

Diseases related to Major Depressive Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 163)
# Related Disease Score Top Affiliating Genes
1 depression 33.8 BDNF CRH DISC2 HTR1A HTR2A SLC6A4
2 endogenous depression 33.6 BDNF CRH SLC6A4
3 anxiety 33.5 BDNF CRH HTR1A HTR2A SLC6A4 TPH1
4 generalized anxiety disorder 32.4 BDNF HTR1A HTR2A SLC6A4 TPH1
5 panic disorder 32.1 BDNF CRH HTR1A HTR2A SLC6A4 TPH1
6 bipolar i disorder 32.0 BDNF HTR1A HTR2A SLC6A4
7 personality disorder 31.9 BDNF DRD4 HTR1A HTR2A SLC6A4 TPH1
8 post-traumatic stress disorder 31.8 BDNF CRH FKBP5 HTR2A SLC6A4
9 borderline personality disorder 31.8 BDNF FKBP5 HTR1A HTR2A SLC6A4 TPH1
10 obsessive-compulsive disorder 31.6 BDNF DRD4 HTR1A HTR2A SLC6A4 TPH1
11 dysthymic disorder 31.6 HTR2A SLC6A4
12 anorexia nervosa 31.5 BDNF CRH HTR2A SLC6A4
13 chronic fatigue syndrome 31.5 CRH HTR1A SLC6A4 TPH2
14 alcohol dependence 31.5 BDNF CHRM2 DRD4 HTR1A HTR2A SLC6A4
15 fibromyalgia 31.4 CRH HTR2A SLC6A4
16 postpartum depression 31.4 BDNF CRH HTR1A SLC6A4
17 attention deficit-hyperactivity disorder 31.4 BDNF DRD4 HTR1A HTR2A SLC6A4 TPH1
18 conduct disorder 31.3 DRD4 SLC6A4 TPH1
19 schizophrenia 31.3 BDNF DISC2 DRD4 HTR1A HTR2A SLC6A4
20 paranoid schizophrenia 31.3 BDNF HTR2A SLC6A4 TPH2
21 eating disorder 31.3 BDNF CRH SLC6A4
22 bipolar disorder 31.1 BDNF CRH DISC2 DRD4 HTR1A HTR2A
23 disease of mental health 30.9 APOE BDNF CRH DRD4 HTR1A HTR2A
24 social phobia 30.9 HTR1A SLC6A4
25 mood disorder 30.8 BDNF CRH DISC2 DRD4 HTR1A HTR2A
26 kleptomania 30.7 HTR1A SLC6A4
27 schizoaffective disorder 30.7 BDNF DISC2 HTR2A SLC6A4
28 heroin dependence 30.1 BDNF DRD4
29 major depressive disorder 1 12.3
30 major depressive disorder 2 12.3
31 mal de debarquement syndrome 11.8
32 psychosexual disorder 11.3 HTR1A HTR2A SLC6A4
33 periodic limb movement disorder 11.3 HTR1A HTR2A SLC6A4
34 alzheimer disease 5 11.2 HTR2A SLC6A4
35 serotonin syndrome 11.2 HTR1A HTR2A SLC6A4
36 pathological gambling 11.2 DRD4 HTR2A SLC6A4
37 brunner syndrome 11.2 HTR1A SLC6A4 TPH1
38 bulimia nervosa 11.2 BDNF HTR2A SLC6A4
39 early-onset schizophrenia 11.2 BDNF DRD4 HTR2A SLC6A4
40 oppositional defiant disorder 11.2 DRD4 SLC6A4 TPH2
41 schizoid personality disorder 11.2 HTR1A HTR2A
42 tic disorder 11.2 DRD4 HTR2A TPH2
43 drug dependence 11.1 BDNF CHRM2 CRH SLC6A4
44 migraine without aura 11.1 DRD4 HTR1A SLC6A4
45 hypoactive sexual desire disorder 11.1 HTR1A HTR2A
46 substance-induced psychosis 11.1 HTR1A HTR2A
47 sudden infant death syndrome 11.1 BDNF HTR1A HTR2A SLC6A4 TPH1 TPH2
48 substance abuse 11.1 BDNF DRD4 SLC6A4
49 irritable bowel syndrome 11.1 CRH SLC6A4 TPH1
50 migraine with or without aura 1 11.1 DRD4 HTR1A HTR2A SLC6A4 TPH1

Comorbidity relations with Major Depressive Disorder via Phenotypic Disease Network (PDN): (show top 50) (show all 55)


Acute Cystitis Adjustment Disorder
Alcohol Abuse Alzheimer Disease
Anorexia Nervosa Anxiety
Atypical Depressive Disorder Avoidant Personality Disorder
Bipolar Disorder Borderline Personality Disorder
Bronchitis Cerebral Atherosclerosis
Cerebral Degeneration Chronic Myocardial Ischemia
Conversion Disorder Decubitus Ulcer
Deficiency Anemia Delusional Disorder
Dependent Personality Disorder Dysthymic Disorder
Eating Disorder Esophagitis
Generalized Anxiety Disorder Heart Disease
Histrionic Personality Disorder Hypertension, Essential
Hypochondriasis Hypothyroidism
Iron Deficiency Anemia Irritable Bowel Syndrome
Ischemic Heart Disease Major Affective Disorder 9
Mitral Valve Disease Mood Disorder
Narcissistic Personality Disorder Obsessive-Compulsive Disorder
Obsessive-Compulsive Personality Disorder Opioid Addiction
Osteoarthritis Osteoporosis
Paralytic Ileus Paranoid Personality Disorder
Paranoid Schizophrenia Parkinson Disease, Late-Onset
Personality Disorder Post-Traumatic Stress Disorder
Protein-Energy Malnutrition Respiratory Failure
Schizoid Personality Disorder Schizophrenia

Graphical network of the top 20 diseases related to Major Depressive Disorder:



Diseases related to Major Depressive Disorder
Sources

Symptoms & Phenotypes for Major Depressive Disorder

About this section

Clinical features from OMIM:

608516

UMLS symptoms related to Major Depressive Disorder:


mental and behavioral signs and symptoms, depressive symptoms

MGI Mouse Phenotypes related to Major Depressive Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.4 APOE BDNF CHRM2 CRH DRD4 FKBP5
Sources

Drugs & Therapeutics for Major Depressive Disorder

About this section

Drugs for Major Depressive Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 611)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
2
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 54910-89-3 3386
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59729-33-8 2771
5
Fluvoxamine Approved, Investigational Phase 4,Not Applicable 54739-18-3 3404 5324346
6
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61869-08-7 43815
7
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 79617-96-2 68617
8
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 34841-39-9, 34911-55-2 444
9
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
10
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 75614-87-8, 51-45-6 774
11
Mianserin Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 24219-97-4 4184
12
Mirtazapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85650-52-8, 61337-67-5 4205
13
Norepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-41-2 439260
14
Trazodone Approved, Investigational Phase 4,Phase 3 19794-93-5 5533
15
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 129722-12-9 60795
16
Reboxetine Approved, Investigational Phase 4,Phase 2,Not Applicable 98769-81-4, 71620-89-8 123628 65856
17
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
18
Diphenhydramine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-24-0, 58-73-1 3100
19
Promethazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60-87-7 4927
20
Suvorexant Approved, Investigational Phase 4 1030377-33-3
21
Eszopiclone Approved, Investigational Phase 4,Phase 3 138729-47-2 969472
22
Buspirone Approved, Investigational Phase 4,Phase 2 36505-84-7 2477
23
Acetylcholine Approved Phase 4,Phase 2 51-84-3 187
24
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
25
Ropinirole Approved, Investigational Phase 4,Not Applicable 91374-20-8, 91374-21-9 5095 497540
26
Amitriptyline Approved Phase 4,Phase 3,Phase 2,Not Applicable 50-48-6 2160
27
Nortriptyline Approved Phase 4,Phase 1,Phase 2,Not Applicable 72-69-5 4543
28
Perphenazine Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-39-9 4748
29
Trimipramine Approved Phase 4 739-71-9 5584 4055
30
Milnacipran Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 92623-85-3 65833
31
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 6740-88-1 3821
32
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
33
Remifentanil Approved Phase 4 132875-61-7 60815
34
Imipramine Approved Phase 4,Not Applicable 50-49-7 3696
35
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 148553-50-8 5486971
36
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 84057-84-1 3878
37
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 132539-06-1 4585
38
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
39
Moclobemide Approved, Investigational Phase 4,Not Applicable,Early Phase 1 71320-77-9 4235
40
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 106266-06-2 5073
41
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-11-5 942 89594
42
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 52485-79-7 40400 644073
43
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-23-7 5754
44
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 10118-90-8 5281021
45
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
46
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
47
Methylphenidate Approved, Investigational Phase 4,Phase 3 113-45-1 4158
48
Simvastatin Approved Phase 4,Phase 1 79902-63-9 54454
49
Tibolone Approved, Investigational Phase 4,Phase 1 5630-53-5
50
Ondansetron Approved Phase 4,Phase 1 99614-02-5 4595

Interventional clinical trials:

(show top 50) (show all 2432)
# Name Status NCT ID Phase Drugs
1 Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
2 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
3 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
4 Major Depressive Disorder - Understanding The Link Between The Brain And The Heart Unknown status NCT01568307 Phase 4 Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
5 Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN) Unknown status NCT02051413 Phase 4 Venlafaxine extended release
6 Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD) Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
7 Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder Unknown status NCT01696617 Phase 4 Aripiprazole 6-week group;Aripiprazole 8-week group
8 Inflammatory Markers and Cognitive Function in Major Depression Unknown status NCT01391221 Phase 4 Duloxetine
9 Lexapro®'s Efficacy After Dose Escalation in Remission Study Unknown status NCT01594866 Phase 4 escitalopram;escitalopram
10 Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder Unknown status NCT02129751 Phase 4 bupropion hydrobromide;Placebo
11 Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
12 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
13 Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
14 Duloxetine for Major Depression in Peri-/Postmenopausal Women Unknown status NCT00889369 Phase 4 Duloxetine
15 Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
16 Neurochemical, Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
17 Effect of Partial Sleep Deprivation on Cognition and Cytokines in Individuals With Major Depression Unknown status NCT00291239 Phase 4
18 A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia Unknown status NCT02669030 Phase 4 suvorexant;Placebo
19 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
20 Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
21 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
22 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4 Escitalopram
23 Effect of Antidepressants on White Matter Structure Unknown status NCT01492621 Phase 4 Desvenlafaxine
24 Efficacy Study of Botox for Depression Unknown status NCT01556971 Phase 4 Botox;Saline Solution
25 International Study to Predict Optimised Treatment - in Depression Unknown status NCT00693849 Phase 4 Escitalopram;Sertraline;Venlafaxine-XR
26 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
27 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
28 Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4 Using Citalopram(drug) or Paroxetine(drug)
29 Benefits of Switching Antidepressants Following Early Nonresponse Unknown status NCT00519012 Phase 4 Sertraline to Paroxetine;Paroxetine to Sertraline
30 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
31 Antidepressant Maintenance in Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
32 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4 Venlafaxine;Fluoxetine
33 A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care Unknown status NCT00939250 Phase 4
34 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression. Unknown status NCT00335205 Phase 4 ropinirole
35 Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Unknown status NCT02237937 Phase 4 Paroxetine;Sertraline;Citalopram;Venlafaxine;Amitriptyline;Escitalopram;Amitriptylinoxide;Nortriptyline;Trimipramine
36 Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression Unknown status NCT01390662 Phase 4
37 Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4 Milnacipran;Placebo
38 Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
39 The Effects of Remifentanil on Attenuating the Hemodynamic Responses After Electroconvulsive Therapy Unknown status NCT02271555 Phase 4 Sevoflurane;Remifentanil;Saline
40 Depression Care Management for Depressed Elders in China Primary Care Unknown status NCT01287494 Phase 4 Sertraline
41 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
42 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
43 SmartTouch Catheter for Left Anterior Line - SmarT Line Study Unknown status NCT02217657 Phase 4
44 Imipramine and Pregabalin Combination in Painful Polyneuropathy Unknown status NCT01047488 Phase 4 Imipramine;Pregabalin;Imipramine, pregabalin;Placebo
45 Safety and Efficacy of Vilazodone in Major Depressive Disorder Completed NCT01473381 Phase 4 Vilazodone;Placebo to citalopram;Placebo to vilazodone;Citalopram
46 Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder Completed NCT01473394 Phase 4 Dose-matched placebo;Vilazodone
47 Safety and Efficacy of Vilazodone in Major Depressive Disorder Completed NCT01573598 Phase 4 Placebo;Vilazodone;Vilazodone
48 Effects of Treatment on Decision-making in Major Depression Completed NCT01916824 Phase 4 Any FDA Approved Antidepressant
49 Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder Completed NCT01148472 Phase 4 Escitalopram;Duloxetine
50 Wellbutrin XL, Major Depressive Disorder and Breast Cancer Completed NCT00234195 Phase 4 bupropion extended release (Wellbutrin XL)

Search NIH Clinical Center for Major Depressive Disorder

Cochrane evidence based reviews: depressive disorder, major

Sources

Genetic Tests for Major Depressive Disorder

About this section

Genetic tests related to Major Depressive Disorder:

# Genetic test Affiliating Genes
1 Major Depressive Disorder 29 FKBP5 HTR2A TPH2
Sources

Anatomical Context for Major Depressive Disorder

About this section

MalaCards organs/tissues related to Major Depressive Disorder:

41
Brain, Testes, Heart, Cortex, Prefrontal Cortex, Pituitary, Amygdala
Sources

Publications for Major Depressive Disorder

About this section

Articles related to Major Depressive Disorder:

(show top 50) (show all 1696)
# Title Authors Year
1
The Cognitive Reserve Should Be Controlled When Using Neuroimaging to Assess Relapse in Major Depressive Disorder-Reply. ( 29955762 )
2018
2
Alterations in Serum BDNF and GDNF Levels after 12 Weeks of Antidepressant Treatment in Female Outpatients with Major Depressive Disorder. ( 29945425 )
2018
3
The Cognitive Reserve Should Be Controlled When Using Neuroimaging to Assess Relapse in Major Depressive Disorder. ( 29955790 )
2018
4
Ratings surveillance and reliability in a study of major depressive disorder with subthreshold hypomania (mixed features). ( 29943445 )
2018
5
Functional brain abnormalities in major depressive disorder using the Hilbert-Huang transform. ( 29427063 )
2018
6
Cerebrospinal fluid D-serine concentrations in major depressive disorder negatively correlate with depression severity. ( 28985587 )
2018
7
Development of a Strategic Tool for Shared Decision-Making in the Use of Antidepressants among Patients with Major Depressive Disorder: A Focus Group Study. ( 29970848 )
2018
8
Oxidative stress in patients with refractory temporal lobe epilepsy and mesial temporal sclerosis: Possible association with major depressive disorder? ( 29414551 )
2018
9
Major depressive disorder: Longitudinal analysis of impact on clinical and behavioural outcomes in Uganda. ( 29424787 )
2018
10
A machine learning framework involving EEG-based functional connectivity to diagnose major depressive disorder (MDD). ( 28702811 )
2018
11
Major depressive disorder and access to health services among people who use illicit drugs in Vancouver, Canada. ( 29351757 )
2018
12
Major depressive disorder and depressive symptoms in intermittent explosive disorder. ( 29455060 )
2018
13
ERP investigation of attentional disengagement from suicide-relevant information in patients with major depressive disorder. ( 28846957 )
2018
14
Therapeutic Antidepressant Potential of NONHSAG045500 in Regulating Serotonin Transporter in Major Depressive Disorder. ( 29955033 )
2018
15
Prevalence of suicidal behaviors in patients with major depressive disorder in China: A comprehensive meta-analysis. ( 28779680 )
2018
16
Brief Report: Major Depressive Disorder with Psychotic Features in Williams Syndrome: A Case Series. ( 29164439 )
2018
17
Model-based comparing efficacy of fluoxetine between elderly and non-elderly participants with major depressive disorder. ( 29324370 )
2018
18
Insights into Macrophage Heterogeneity and Cytokine-Induced Neuroinflammation in Major Depressive Disorder. ( 29941796 )
2018
19
Distinguishing Subgroups Based on Psychomotor Functioning among Patients with Major Depressive Disorder. ( 29975958 )
2018
20
Multimodal Treatment With ECT for Identity Integration in a Patient With Dissociative Identity Disorder, Complex Post-traumatic Stress Disorder, and Major Depressive Disorder: A Rare Case Report. ( 29977211 )
2018
21
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. ( 29450462 )
2018
22
Increased cerebrospinal fluid complement C5 levels in major depressive disorder and schizophrenia. ( 29454970 )
2018
23
Change in 1-year hospitalization of overall and older patients with major depressive disorder after second-generation antipsychotics augmentation treatment. ( 29407535 )
2018
24
A Randomized, Double-Blind, Placebo-Controlled Trial of Escitalopram in Patients with Asthma and Major Depressive Disorder. ( 29409976 )
2018
25
MicroRNA132 associated multimodal neuroimaging patterns in unmedicated major depressive disorder. ( 29408968 )
2018
26
Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder. ( 29185786 )
2018
27
Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder. ( 29955151 )
2018
28
Disrupted topology of hippocampal connectivity is associated with short-term antidepressant response in major depressive disorder. ( 28866298 )
2018
29
Depression With Mixed Features in Major Depressive Disorder: A New Diagnosis or There All Along? ( 29419949 )
2018
30
Altered spontaneous brain activity in MRI-negative refractory temporal lobe epilepsy patients with major depressive disorder: A resting-state fMRI study. ( 29406962 )
2018
31
In Silico Preliminary Association of Ammonia Metabolism Genes GLS, CPS1, and GLUL with Risk of Alzheimer's Disease, Major Depressive Disorder, and Type 2 Diabetes. ( 29441491 )
2018
32
Effects of tandospirone augmentation in major depressive disorder patients with high anxiety: A multicenter, randomized, parallel-controlled, open-label study. ( 29433063 )
2018
33
A novel relationship for schizophrenia, bipolar and major depressive disorder Part 3: Evidence from chromosome 3 high density association screen. ( 28856687 )
2018
34
The Compelling and Persistent Problem of Bipolar Disorder Disguised as Major Depression Disorder: An Integrative Review [Formula: see text]. ( 29952230 )
2018
35
Axonal myelin decrease in the splenium in major depressive disorder. ( 29980921 )
2018
36
Does intensity or youth affect the neurobiological effect of exercise on major depressive disorder? ( 27693226 )
2018
37
Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive Disorder in Japan (PERFORM-J): Protocol for a Prospective Cohort Study. ( 29941418 )
2018
38
Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder. ( 29451287 )
2018
39
Patterns of cannabis use and clinical correlates among individuals with Major Depressive Disorder and Bipolar Disorder. ( 29069624 )
2018
40
Seeing the signs: Using the course of residual depressive symptomatology to predict patterns of relapse and recurrence of major depressive disorder. ( 29228458 )
2018
41
Accelerated Magnetic Seizure Therapy for Treatment of Major Depressive Disorder: A Report of 3 Cases. ( 29979250 )
2018
42
Patterns of co-occurring addictions, posttraumatic stress disorder, and major depressive disorder in detoxification treatment seekers: Implications for improving detoxification treatment outcomes. ( 29415850 )
2018
43
Will imaging individual raphe nuclei in males with major depressive disorder enhance diagnostic sensitivity and specificity? ( 29365217 )
2018
44
Plasma amino acid profile in major depressive disorder: Analyses in two independent case-control sample sets. ( 28950111 )
2018
45
The effect of childhood trauma on blood transcriptome expression in major depressive disorder. ( 29975859 )
2018
46
Number of illness episodes as predictor of residual symptoms in major depressive disorder. ( 28988102 )
2018
47
Resilience Dysregulation in Major Depressive Disorder: Focus on Glutamatergic Imbalance and Microglial Activation. ( 28676011 )
2018
48
Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome. ( 29235884 )
2018
49
Eating styles in major depressive disorder: Results from a large-scale study. ( 29175296 )
2018
50
Spatiotemporal, metabolic, and therapeutic characterization of altered functional connectivity in major depressive disorder. ( 29341320 )
2018